Stem cell treatment for Alzheimer’s gets Americord support

Kathy Mahdoubi | | Health Imaging | Molecular Imaging

An investigational therapy called Neurostem-AD developed by Medipost to treat the neurodegeneration caused by Alzheimer’s disease is currently in clinical trials and is now receiving financial backing from Americord, a cord blood, tissue and placenta bank, Americord officials announced today.

Neurostem-AD uses human umbilical cord blood mesenchymal stem cells. A statement from Americord notes that this is the first donation the cord blood bank has made under its corporate giving program for the development of new stem cell therapies based on umbilical cord, cord tissue and tissue derived from placentas.

"At Americord, we are committed to assisting the world's leading scientists as they pursue cutting edge stem cell-based therapies for diseases and conditions that have long-proved to be difficult or impossible to treat," Americord CEO Martin Smithmyer said in the statement. "We are thrilled to make a donation to Medipost to support their research into the treatment of Alzheimer's disease with a stem cell-based therapy."

The clinical trial was established in February 2014 and is scheduled to run until December 2015.

Kathy Mahdoubi

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.